[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE312828T1 - Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung - Google Patents

Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung

Info

Publication number
ATE312828T1
ATE312828T1 AT02794623T AT02794623T ATE312828T1 AT E312828 T1 ATE312828 T1 AT E312828T1 AT 02794623 T AT02794623 T AT 02794623T AT 02794623 T AT02794623 T AT 02794623T AT E312828 T1 ATE312828 T1 AT E312828T1
Authority
AT
Austria
Prior art keywords
preparation
therapeutic use
acylaminothiazole derivatives
acylaminothiazole
derivatives
Prior art date
Application number
AT02794623T
Other languages
English (en)
Inventor
Cointet Paul De
Pierre Despeyroux
Daniel Frehel
Chantal Guenet
Corinne Heckel
Jean-Pierre Maffrand
Rebecca Pruss
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0207222A external-priority patent/FR2840899B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE312828T1 publication Critical patent/ATE312828T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT02794623T 2001-08-06 2002-08-05 Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung ATE312828T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0110504 2001-08-06
FR0207222A FR2840899B1 (fr) 2002-06-12 2002-06-12 Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
PCT/FR2002/002802 WO2003014095A1 (fr) 2001-08-06 2002-08-05 Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique

Publications (1)

Publication Number Publication Date
ATE312828T1 true ATE312828T1 (de) 2005-12-15

Family

ID=26213132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794623T ATE312828T1 (de) 2001-08-06 2002-08-05 Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung

Country Status (10)

Country Link
US (2) US7288659B2 (de)
EP (1) EP1417189B1 (de)
JP (1) JP2005500370A (de)
AR (1) AR039059A1 (de)
AT (1) ATE312828T1 (de)
DE (1) DE60208044T2 (de)
DK (1) DK1417189T3 (de)
ES (1) ES2254773T3 (de)
TW (1) TWI318974B (de)
WO (1) WO2003014095A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI314928B (en) * 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
MXPA05002420A (es) * 2002-10-09 2005-10-05 Pfizer Prod Inc Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006525990A (ja) * 2003-05-12 2006-11-16 ファイザー・プロダクツ・インク 神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物
CA2534529A1 (en) * 2003-08-06 2005-02-24 Pfizer Products Inc. Oxazole compounds for the treatment of neurodegenerative disorders
BRPI0506880A (pt) * 2004-01-16 2007-06-26 Sanofi Aventis derivados de acilaminotiazol, sua preparação e sua aplicação em terapêutica
ATE517098T1 (de) 2004-01-16 2011-08-15 Sanofi Sa Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
MY149143A (en) * 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
EP2173728A2 (de) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclische pkb-modulatoren
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CN109071503A (zh) * 2016-03-31 2018-12-21 默克专利有限公司 用于抑制亲环素的化合物及其用途
WO2019142883A1 (ja) 2018-01-18 2019-07-25 第一三共株式会社 ジヒドロインドリジノン誘導体
JP7553030B2 (ja) 2019-07-08 2024-09-18 国立大学法人東京工業大学 ジヒドロインドリジノン誘導体を用いたインスリン産生細胞の作製法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016751A1 (es) * 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
ATE296797T1 (de) 1996-11-22 2005-06-15 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl) amino saüre amide,pharmazeutische zusammensetzungen damit, und methodenzur inhibierung beta-amyloid peptid freisetzung oder synthese
CN1616432A (zh) * 1996-12-23 2005-05-18 伊兰药品公司 化合物、其用途以及含有所述化合物的药物组合物
AR011164A1 (es) * 1997-02-28 2000-08-02 Lilly Co Eli Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o su sintesismediante el uso de dichos compuestos
WO2000019210A2 (en) * 1998-09-30 2000-04-06 Elan Pharmaceuticals, Inc. Determining the mechanism of beta-amyloid peptide generation
WO2000024392A1 (fr) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide

Also Published As

Publication number Publication date
US20080058380A1 (en) 2008-03-06
ES2254773T3 (es) 2006-06-16
JP2005500370A (ja) 2005-01-06
DE60208044T2 (de) 2006-08-17
DK1417189T3 (da) 2006-05-08
EP1417189A1 (de) 2004-05-12
AR039059A1 (es) 2005-02-09
EP1417189B1 (de) 2005-12-14
US7288659B2 (en) 2007-10-30
DE60208044D1 (de) 2006-01-19
TWI318974B (en) 2010-01-01
WO2003014095A1 (fr) 2003-02-20
US20040171643A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
DE60203917D1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate, deren herstellung und deren therapeutische verwendung
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
DE60107859D1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
DE50209483D1 (de) Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE60336907D1 (de) Spirobifluorenderivate, deren herstellung und deren verwendung
DE60209779D1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE60323754D1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE231869T1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE60235547D1 (de) En daraus, deren herstellung und verwendung
DE60130834D1 (de) Zusammensetzungen gegen schlechte Gerüche, deren Herstellung und Verwendung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE60307632D1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE357448T1 (de) Benzoxazinonderivative, deren herstellung und verwendung
DE602004017463D1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
ATE242197T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
ATE261959T1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
DE60103054D1 (de) Phenyloxazol-1,4-diazabicyclo[3.2.2]nonanderivate, ihre herstellung und ihre therapeutische verwendung
DE60005690D1 (de) Titanverbindungen, deren herstellung und verwendung
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1417189

Country of ref document: EP